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Description

Coronavirus infectious disease 2019 (COVID-19) has become one of the most recognized
viral illnesses to date. Most people infected with the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) have a benign clinical course, but there have also been catastrophic outcomes. Although, notoriously known to affect the respiratory system, extra-pulmonary manifestations have also been established. An increasing number of people have
been reported to present with cardiac manifestations, which include but are not limited
to arrhythmias. The cardiac conduction system can be damaged by various mechanisms in
patients infected with SARS-CoV-2. In this review, we will attempt to briefly describe the
arrhythmogenic potential of SARS-CoV-2 and the factors that play a key role in the electrophysiological pathology seen in COVID-19.
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Introduction and Background

Cardiac manifestations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection have been well established in recent
literature. One study has shown patients
with underlying cardiovascular disease who
are infected with coronavirus disease 2019
(COVID-19) have a 10.5% fatality rate.1 Cardiac
injury or damage has been observed in patients
with COVID-19. In a retrospective study done
by Zhou et al., patients infected with SARSCoV-2 were found to have various cardiac manifestations. Heart failure was the third most
common (23%) observed complication in the
study population. Cardiac sensitive troponin
I was found in more than half of the patients
who did not survive.2 A retrospective observational study conducted by Yang and colleagues
found that cardiac injury (defined as elevated
troponin I levels) was present in 23% of patients.3 Another study exhibited that among 138
hospitalized patients infected with COVID-19,
16.7% developed arrhythmias.4 In another ret-

rospective multicenter study, 40% of fatalities
were attributed to myocardial injury.5 Finally,
a study conducted by Du et al. determined
that 8.6% of deaths in the study population
were from cardiac arrest.6 Thus, infection with
SARS-CoV-2 is associated with cardiac injury,
which may manifest as arrhythmias. (Figure 1)

Review

Damage to the myocardium may manifest as
conduction system damage, tachyarrhythmias,
bradyarrhythmias, drug-induced QT prolongation and sudden cardiac death have been
described within the literature. Arrhythmias
seen with COVID-19 include sinus tachycardia,
sinus bradycardia, atrioventricular block, bundle
branch block, atrial fibrillation, supraventricular
tachycardia, torsade des pointes, non-sustained
ventricular tachycardia, sustained ventricular
tachycardia, ventricular fibrillation and pulseless electrical activity.7 A recent cross-sectional
survey was sent to more than 1,100 electrophysiologists worldwide to evaluate the ar-
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Figure 1. Graph depicting the incidence of cardiac manifestations seen in COVID-19, as per multiple studies.1-6
rhythmic manifestations of COVID-19. According to the results of the survey, severe sinus
bradycardia and complete heart block were the
most commonly reported bradyarrhythmia and
atrial fibrillation as the most common tachyarrhythmia reported amongst hospitalized
patients with COVID-19.8
Most of the arrhythmias that have been documented have occurred in the hospital setting.
Wang et al. demonstrated that in hospitalized
patients with COVID-19, 16.7% patients had
a documented arrhythmia and of those 44%
were admitted in the intensive care unit (ICU).4
A cohort study done in New York established
that atrial arrhythmias were seen in 17.7% of
patients requiring mechanical ventilation and
only 1.9% of patients on non-invasive ventilation.9 Bhatla et al. conducted a cohort study
to evaluate the incidence of cardiac arrest and
various arrhythmias in hospitalized patients.
This study exhibited that a higher incidence
of cardiac arrest and arrhythmias was seen in
patients admitted to the ICU when compared
to the non-ICU population.10
Arrhythmias have become a well-recognized
manifestation of COVID-19. Several theories
exist as to why cardiac arrhythmias are present
in COVID-19 patients. (Figure 2) First, mechanisms of arrythmias include direct myocardial
damage, which can directly damage myocardial
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cells by setting up an inflammatory response.
After entering the myocardium, the virus proliferates, causing oxidative stress and direct
injury to the cardiac myocytes. An inflammatory response is then initiated by the host. The
host response includes T cell activation, cytokine release and antibody formation. This leads
to interstitial edema, endothelial dysfunction
and cardiac fibrosis. Cardiac remodeling and
dilatation is seen, which leads to an impaired
myocardium. Acute viral myocarditis and pericarditis occur as a result and can be self-limiting with minimal symptoms, but occasionally,
atrial or ventricular arrhythmias can be seen as
a consequence.11,12
Second, hypoxia, a known complication of
COVID-19 infection, is also a well-recognized
risk factor for arrhythmias. Given the immense
pulmonary involvement of SARS-CoV-2, hypoxia is one of the major sequelae seen in
COVID-19. Acute lung injury can lead to hypoxemia, which can trigger instability in the myocardial electrical balance. As a result, decreased
oxygen delivery can alter the action potential
and has contributed to arrhythmias encountered during this pandemic.13,14
Next, the host immune response to the virus
itself may also contribute to arrhythmogenesis.
Inflammatory mediator release of interleukin-1
(IL-1), IL-6, IL-7, interferon-gamma and tumor
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Figure 2. Various mechanisms implicated in causing arrhythmias in COVID-19.
necrosis-alpha are postulated to adversely affect cardiac repolarization. These inflammatory
mediators may inhibit a cardiac ion channel
protein of the delayed rectified current, Ikr. The
functional blockade of Ikr may lead to delayed
repolarization and subsequent prolonged QT on
electrocardiogram (ECG).15,16
Furthermore, electrolyte derangement, specifically hypokalemia, is associated with SARSCoV-2 infection. As electrolyte imbalances,
specifically hypokalemia, have been proven to
cause arrhythmias, patients with COVID-19 potentially can be more susceptible to developing
arrhythmias. The virus enters the host via the
ACE2 receptor, which can alter the renin-angiotensin-aldosterone system (RAAS). The virus
may degrade the ACE2 receptors, disrupting
their ability to regulate the RAAS, leading to
electrolyte imbalances. Another source of
hypokalemia in these patients is due to gastrointestinal symptoms (diarrhea and vomiting).17,18
In the cohort study conducted by Chen et al.,
hypokalemia was seen in 85% of patients who
were critically ill with COVID-19.18 Close monitoring on telemetry is advisable, as is consulting a cardiologist for these patients earlier in
the course of the disease. It is also important
to note that over-correction of electrolytes can
also precipitate certain arrhythmias.
Finally, medications used in the management

of SARS-CoV-2 can also lead to arrhythmias.
While treating COVID-19 effectively is important, physicians and other medical providers must ensure that therapeutic agents are
renally dosed and drug-drug interactions that
potentiate QT-prolongation are eliminated.
Drugs that are used include, anti-virals, immunosuppressants, anti-arrhythmics, antibiotics,
anti-psychotics and anti-emetics. The use of
these medications (alone or in combination)
can cause prolonged QT, torsades de pointes,
atrioventricular block, supraventricular tachycardia and bradycardia.19,20 Medications should
also be renally dosed for patients with renal
insufficiency. A detailed list of medications
and their respective cardiac manifestations are
provided in Table 1.

Conclusion

COVID-19 has been shown to be pro-arrhythmogenic, and arrhythmias are underappreciated as a cause of increased morbidity and
mortality. Infection results in inflammatory
conditions that may further precipitate arrhythmias. Health care providers should be
cognizant of monitoring with telemetry those
at highest risks for arrhythmias, which would
include patients with cardiac injury (patients
with elevated troponin), those who have
structural heart disease and known history of
arrhythmias. Prevention includes obtaining
baseline ECG while monitoring with telemetry,
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Table 1. A list of some drugs used in the management of COVID-19 and their respective cardiac
manifestations.19,20
Drug Name

Drug Class

Possible Cardiac Side Effect

Amiodarone

Anti-arrhythmic

QT prolongation

Flecainide

Anti-arrhythmic

QT prolongation

Ibutilide

Anti-arrhythmic

QT prolongation

Procainamide

Anti-arrhythmic

QT prolongation

Quinidine

Anti-arrhythmic

QT prolongation

Sotalol

Anti-arrhythmic

QT prolongation

Azithromycin

Antibiotic

QT prolongation

Levofloxacin

Antibiotic

QT prolongation

Fluconazole

Anti-fungal

QT prolongation

Domeperidone

Anti-emetic

QT prolongation

Odansetron

Anti-emetic

QT prolongation

Haloperidol

Anti-psychotic

QT prolongation

Resperidone

Anti-psychotic

QT prolongation

Chloroquine

Anti-malarial

QT prolongation

Hydroxychloroquine

Anti-malarial

QT prolongation

Propofol

Anesthetic

QT prolongation

Ribavirin

Anti-viral

Tachycardia, MI, Cardiomyopathy, arryhtmia

Lopinavir/Ritonavir

Anti-viral

Ischemia Events, Atrioventricular block

Methyprednisone

Steroid

Electrolyte imbalances

Tocilizumab, Eculizumab

Immunosuppressants

Bradycardia, Atrioventricular block

Bevacizumab

Immunosuppressants

Congestive heart failure, Supraventricular
tachycardia

with emphasis on QTc or AV block, avoiding QT
prolonging medications, reducting inflammatory response and consulting electrophysiology early, when necessary. High-risk patients
should practice social distancing and be cautious of potential QT prolonging medications,
consulting their physician when using them.
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